Last reviewed · How we verify
Dolutegravir Pill
Dolutegravir Pill is a Small molecule drug developed by University of Nairobi. It is currently FDA-approved. Also known as: Tivicay.
At a glance
| Generic name | Dolutegravir Pill |
|---|---|
| Also known as | Tivicay |
| Sponsor | University of Nairobi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH) (PHASE4)
- Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance (PHASE3)
- B/F/TAF to DTG/3TC Switch Study (PHASE3)
- Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (PHASE4)
- DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: (PHASE4)
- Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully (PHASE2)
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (PHASE4)
- Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir Pill CI brief — competitive landscape report
- Dolutegravir Pill updates RSS · CI watch RSS
- University of Nairobi portfolio CI
Frequently asked questions about Dolutegravir Pill
What is Dolutegravir Pill?
Dolutegravir Pill is a Small molecule drug developed by University of Nairobi.
Who makes Dolutegravir Pill?
Dolutegravir Pill is developed and marketed by University of Nairobi (see full University of Nairobi pipeline at /company/university-of-nairobi).
Is Dolutegravir Pill also known as anything else?
Dolutegravir Pill is also known as Tivicay.
What development phase is Dolutegravir Pill in?
Dolutegravir Pill is FDA-approved (marketed).
Related
- Manufacturer: University of Nairobi — full pipeline
- Also known as: Tivicay
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing